pharmaceutical investing Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006
pharmaceutical investing Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125
pharmaceutical investing Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
pharmaceutical investing Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles
pharmaceutical investing Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones
Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors
pharmaceutical investing Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
